Scientists use nanomaterials to localize and control drug deliveryJanuary 23, 2008System is invisible to the immune system, preventing response Using nanotechnology, scientists from UCLA and Northwestern University have developed a localized and controlled drug delivery method that is invisible to the immune system, a discovery that could provide newer and more effective treatments for cancer and other diseases. The study, published Jan. 22, 2008 in the journal ACS Nano, provides an example of the enormous potential and clinical significance that nanomaterials may represent in such fields as oncology, endocrinology and cardiology.
The researchers used nanoscale polymer films, about four nanometers per layer, to build a sort of matrix or platform to hold and slowly release an anti-inflammatory drug. The films are orders of magnitude thinner than conventional drug deliver coatings, said Genhong Cheng, a researcher at UCLA's Jonsson Comprehensive Cancer Center and one of the study's authors. A nanometer is one billionth of a meter. "Using this system, drugs could be released slowly and under control for weeks or longer," said Cheng, a professor of microbiology, immunology and molecular genetics. "A drug that is given orally or through the bloodstream travels throughout the system and dissipates from the body much more quickly. Using a more localized and controlled approach could limit side effects, particularly with chemotherapy drugs." Researchers coated tiny chips with layers of the nanoscale polymer films, which are inert and helped provide a Harry Potter-like invisibility cloak for the chips, hiding them from the body's natural defenses. They then added Dexamethasone, an anti-inflammatory drug, between the layers. The chips were implanted in mice, and researchers found that the Dexamethasone-coated films suppressed the expression of cytokines, proteins released by the cells of the immune system to initiate a response to a foreign invader. Mice without implants and those with uncoated implants were studied to compare immune response. The uncoated implants generated an inflammatory response from the surrounding tissue, which ultimately would have led to the body's rejection of the implant and the breakdown of its functionality. However, tissue from the mice without implants and the mice with the nano-cloaked implants were virtually identical, proving that the film-coated implants were effectively shielded from the body's defense system, said Edward Chow, a former UCLA graduate student who participated in the study and is one of its authors. "The polymer films provided a cloak of invisibility for the implants, keeping the immune system from attacking," Chow said. The nanomaterial technology serves as a non-invasive and biocompatible platform for the delivery of a broad range of therapeutics, said Dean Ho, an assistant professor of biomedical and mechanical engineering with the McCormick School of Engineering and Applied Science, a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the study's senior author. The technology also may prove to be an effective approach for delivering multiple drugs, controlling the sequence of multi-drug delivery strategies and enhancing the life spans of commonly implanted devises such as cardiac stents, pacemakers and continuous glucose monitors. "For chemotherapy, this system could enhance treatment efficacy while preventing uncontrolled delivery and the resultant patient side effects," Ho said. "Furthermore, as implantable devices continue to find widespread application in cardiovascular medicine, neural disorders and diabetes, the nano-cloaking capabilities can serve as a widely applicable approach to enhance the lifetime of these devices. This would eliminate unnecessary surgeries and enhance the efficiency of patient care." Many cancer drugs, chemotherapies for example, are delivered systemically through the blood stream. The drugs attack cancer cells, but also other fast growing cells causing side effects such as anemia, nausea and hair loss. If the chemotherapy could be delivered by implant directly to the tumor site, such side effects would be limited, said Cheng, who also is a member of the Center for Cell Control at the UCLA Henry Samueli School of Engineering and Applied Sciences. "Say you have a localized cancer such as breast cancer, the drugs we give are not directly targeted to the breast," Cheng said. "If we could apply the treatment locally and control the release of the drugs, the therapy might be more effective in treating the cancer." Chemotherapy drugs could potentially be placed in high concentration between the polymer films and an implant placed at the tumor site. The drugs would be released slowly, over time, delivering more of the toxic chemicals directly to the cancer cells. This study provided the proof of principle that implants in animal models could be coated with materials that made them invisible to the immune system. Cheng and Ho are now testing in animal models whether cancer therapies can be effectively and safely administered and locally delivered using the nanomaterials. University of California - Los Angeles Science News and Science Current Events Tag Cloud This tag cloud is a visual representation of term frequencies of random science news topics with common terms grouped together and emphasized by their display size. Melanin Glucose Levels Cancer Survivor Fish Oil Infection Ethanol Production Overweight Children Pesticides Adult Stem Cells Cataract Vitamin C Soybean Saturn Signaling Pathway Biodiversity Amphibian Kidney Disease Frogs Viral Infection Sexual Abuse Epstein-barr Virus Cognition Endangered Species Defibrillator Liver Disease
See More: Science News Tags | |||||||||||||||||||||
|
Related Immune System Current Events and Immune System News Articles New clue into how brain stem cells develop into cells which repair damaged tissue The joint research, funded by the National Multiple Sclerosis Society and the UK MS Society as well as the National Institutes of Health and Howard Hughes Medical Institute, was conducted by scientists at the University of California San Francisco (UCSF) and University of Cambridge and was published today (01 July) in the journal Genes and Development. UCLA collaboration identifies immune system link to schizophrenia Schizophrenia is a devastating mental disease, thought to be caused by the interaction of both genetic and environmental factors. Researchers testing virus-gene therapy combination against melanoma Researchers at the Moores UCSD Cancer Center are injecting a modified herpes virus into melanoma tumors, hoping to kill the cancer cells while also bolstering the body's immune defenses against the disease. New lab-on-a-chip measures mechanics of bacteria colonies Researchers at the University of Michigan have devised a microscale tool to help them understand the mechanical behavior of biofilms, slimy colonies of bacteria involved in most human infectious diseases. Study identifies biomarker that safely monitors tumor response to new brain cancer treatment A specific biomarker, a protein released by dying tumor cells, has been identified as an effective tool in an animal model to gauge the response to a novel gene therapy treatment for glioblastoma mulitforme. Mayo Clinic study finds celiac disease 4 times more common than in 1950s Celiac disease, an immune system reaction to gluten in the diet, is over four times more common today than it was 50 years ago, according to findings of a Mayo Clinic study published this month in the journal Gastroenterology. UT researcher: Interferon alpha can delay full onset of type I diabetes A low dose of oral interferon alpha shows promise in preserving beta cell function for patients with newly diagnosed type 1 diabetes, or juvenile diabetes. Gene expression findings a step toward better classification and treatment of juvenile arthritis Scientists have discovered gene expression differences that could lead to better ways to classify, predict outcome, and treat juvenile idiopathic arthritis (JIA). Scripps research scientists find key culprits in lupus The more than 1.5 million Americans with systemic lupus erythematosus (or lupus) suffer from a variety of symptoms that flare and subside, often including painful or swollen joints, extreme fatigue, skin rashes, fever, and kidney problems. Patients with moderate to severe periodontitis need evaluation for heart disease risk Additional research is called for and patients with moderate to severe periodontitis should receive evaluation and possible treatment to reduce their risk of atherosclerotic cardiovascular disease (CVD). More Immune System Current Events and Immune System News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||